Led by CEO Bryan Dechairo, Sherlock Biosciences is a company engineering biology to bring next-generation diagnostics to the point-of-need. Powered by CRISPR and synthetic biology, Sherlock’s proprietary engineering biology tools form the foundation of its decentralized diagnostic platform for DNA and RNA detection. Through its engineering biology tools, CRISPR-based SHERLOCK™ and synthetic biology-based INSPECTR™, the company brings together the accuracy of PCR with the convenience of antigen tests for molecular diagnostics at the point-of-need. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, making it well suited for use in the home and in low resource settings, opening up a wide range of potential applications in areas including infectious disease, early detection of cancer, treatment monitoring, and precision medicine. In 2020 the company made history with the first FDA-authorized use of CRISPR technology.
08/03/2022
